Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
This is a dose escalation study of intravenous drug, RO7297089. Cohorts of at least three patients will be treated in the dose escalation phase and receive escalating doses of RO7297089 to determine a maximum tolerated/administered dose (MTD). Once the dose escalation phase is complete, approximately 30 eligible patients will be enrolled in the dose expansion phase and receive the recommended phase 2 dose (at or below the MTD, determined in the dose escalation phase).